Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMO | O15229 | 1/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.40 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.34 |
| ▸ | ABL1 | P00519 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.33 |
| ▸ | TDO2 | P48775 | 2/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | GLA | P06280 | 1/20 | 0.33 |
| ▸ | HTT | P42858 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.33 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.32 |
| ▸ | MIF | P14174 | 1/20 | 0.31 |
| ▸ | ATR | Q13535 | 1/20 | 0.31 |
| ▸ | CYP19A1 | P11511 | 2/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24087802 | 1.00 | KMO (0.44) | KMOL3MBTL1CYP11B2ABL1KMT2A | |
| SCHEMBL31000813 | 0.75 | KMO (0.63) | KMOL3MBTL1ABL1KMT2ASMN1; SMN2 | |
| SCHEMBL10874992 | 0.70 | L3MBTL1 (0.36) | KMOL3MBTL1CYP11B2ABL1KMT2A | |
| SCHEMBL28761033 | 0.70 | CYP11B2 (0.47) | KMOL3MBTL1CYP11B2SMN1; SMN2 | |
| SCHEMBL3135323 | 0.70 | CYP11B2 (0.47) | KMOL3MBTL1CYP11B2SMN1; SMN2 | |
| SCHEMBL30736060 | 0.68 | CYP11B2 (0.46) | KMOL3MBTL1CYP11B2KMT2AKDM4E | |
| SCHEMBL3196861 | 0.68 | CYP11B2 (0.46) | KMOL3MBTL1CYP11B2KMT2AKDM4E | |
| SCHEMBL11678878 | 0.68 | L3MBTL1 (0.42) | KMOL3MBTL1CYP11B2ABL1KMT2A | |
| SCHEMBL17187786 | 0.68 | FEN1 (0.48) | L3MBTL1TDO2HRH4ATR | |
| SCHEMBL11680105 | 0.68 | L3MBTL1 (0.42) | KMOL3MBTL1CYP11B2ABL1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11339135-B2 | Method for producing triazine compound | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2022-05-24 | — | — | US | disclosed |
| US-20210380541-A1 | METHOD FOR PRODUCING TRIAZINE COMPOUND | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2021-12-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11339135-B2 | Method for producing triazine compound | IL5, IL15, CYP3A5 | KMO 125/4885L3MBTL1 4361/4885CYP11B2 140/4885 |
| US-20210380541-A1 | METHOD FOR PRODUCING TRIAZINE COMPOUND | IL5, IL15, CYP3A5 | KMO 165/4885L3MBTL1 4359/4885CYP11B2 177/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.